Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
Oncocyte (Nasdaq: OCX), a diagnostics technology company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025. CEO Josh Riggs and CFO Andrea James will represent the company, with Riggs scheduled for a fireside chat on April 7, 2025, at 3:45 PM ET.
During the conference, the executives will discuss Oncocyte's innovative diagnostic technologies and highlight their progress in commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach to lead in transplant monitoring solutions.
Investors interested in attending the virtual fireside chat or scheduling one-on-one meetings should contact their Needham sales representative.
Oncocyte (Nasdaq: OCX), un'azienda di tecnologia diagnostica, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute che si svolgerà dal 7 al 10 aprile 2025. L'amministratore delegato Josh Riggs e il CFO Andrea James rappresenteranno l'azienda, con Riggs programmato per una chiacchierata informale il 7 aprile 2025 alle 15:45 ET.
Durante la conferenza, i dirigenti discuteranno delle tecnologie diagnostiche innovative di Oncocyte e metteranno in evidenza i progressi nella commercializzazione di un kit di test per il monitoraggio del rigetto degli organi trapiantati regolamentato. L'azienda sta perseguendo un approccio dirompente per guidare le soluzioni di monitoraggio dei trapianti.
Gli investitori interessati a partecipare alla chiacchierata virtuale o a pianificare incontri one-to-one dovrebbero contattare il loro rappresentante commerciale di Needham.
Oncocyte (Nasdaq: OCX), una empresa de tecnología diagnóstica, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Needham sobre Salud que se llevará a cabo del 7 al 10 de abril de 2025. El CEO Josh Riggs y la CFO Andrea James representarán a la empresa, con Riggs programado para una charla informal el 7 de abril de 2025 a las 3:45 PM ET.
Durante la conferencia, los ejecutivos discutirán sobre las tecnologías diagnósticas innovadoras de Oncocyte y destacarán sus avances en la comercialización de un kit de prueba para el monitoreo del rechazo de trasplantes de órganos regulado. La empresa está persiguiendo un enfoque disruptivo para liderar en soluciones de monitoreo de trasplantes.
Los inversores interesados en asistir a la charla virtual o en programar reuniones uno a uno deben contactar a su representante de ventas de Needham.
온코사이트 (Nasdaq: OCX), 진단 기술 회사,는 2025년 4월 7일부터 10일까지 열리는 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 조쉬 리그스와 CFO 안드레아 제임스가 회사를 대표하며, 리그스는 2025년 4월 7일 오후 3시 45분 ET에 진행되는 대화에 예정되어 있습니다.
컨퍼런스 동안, 경영진은 온코사이트의 혁신적인 진단 기술에 대해 논의하고 규제된 장기 이식 거부 반응 모니터링 테스트 키트의 상용화 진행 상황을 강조할 것입니다. 이 회사는 이식 모니터링 솔루션에서 선도하기 위해 시장을 혼란스럽게 하는 접근 방식을 추구하고 있습니다.
가상 대화에 참석하거나 일대일 회의를 예약하려는 투자자는 니드햄 영업 대표에게 연락해야 합니다.
Oncocyte (Nasdaq: OCX), une entreprise de technologie diagnostique, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé qui se tiendra du 7 au 10 avril 2025. Le PDG Josh Riggs et la CFO Andrea James représenteront l'entreprise, Riggs étant prévu pour une discussion informelle le 7 avril 2025 à 15h45 ET.
Au cours de la conférence, les dirigeants discuteront des technologies diagnostiques innovantes d'Oncocyte et mettront en avant leurs avancées dans la commercialisation d'un kit de test pour le suivi du rejet de greffe d'organes réglementé. L'entreprise adopte une approche perturbatrice pour se positionner en leader dans les solutions de suivi des greffes.
Les investisseurs intéressés à assister à la discussion virtuelle ou à organiser des réunions individuelles doivent contacter leur représentant commercial de Needham.
Oncocyte (Nasdaq: OCX), ein Diagnosetechnologieunternehmen, hat seine Teilnahme an der 24. Virtuellen Gesundheitskonferenz von Needham vom 7. bis 10. April 2025 angekündigt. CEO Josh Riggs und CFO Andrea James werden das Unternehmen vertreten, wobei Riggs am 7. April 2025 um 15:45 Uhr ET für ein informelles Gespräch eingeplant ist.
Während der Konferenz werden die Führungskräfte über die innovativen Diagnosetechnologien von Oncocyte sprechen und ihre Fortschritte bei der Kommerzialisierung eines regulierten Testkits zur Überwachung von Organtransplantationsabstoßungen hervorheben. Das Unternehmen verfolgt einen marktdisruptiven Ansatz, um bei Lösungen zur Überwachung von Transplantationen führend zu sein.
Investoren, die an der virtuellen Gesprächsrunde teilnehmen oder persönliche Meetings planen möchten, sollten ihren Vertriebsmitarbeiter von Needham kontaktieren.
- None.
- None.
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference.
During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies and will highlight the company’s progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte to lead the way in advancing transplant monitoring solutions.
Investors wishing to attend the virtual fireside chat or schedule one-on-one meetings are encouraged to reach out to their Needham sales representative to express interest.
Event: 24th Annual Needham Virtual Healthcare Conference
Dates: April 7-10, 2025
Oncocyte Fireside Chat: April 7, 2025, 3:45 PM (ET)
Location: Virtual
For more information about Oncocyte and its products, please visit www.oncocyte.com.
About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.
For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
Forward-Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte’s progress toward commercializing a regulated organ transplant rejection monitoring test kit, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When is Oncocyte (OCX) presenting at the Needham Healthcare Conference 2025?
What new product is Oncocyte (OCX) developing for transplant patients?
How can investors participate in Oncocyte's (OCX) presentation at the Needham Conference?
What is the focus of Oncocyte's (OCX) presentation at the 2025 Needham Conference?
Which Oncocyte (OCX) executives are attending the 2025 Needham Healthcare Conference?
